Compare Johnson & Johnson (JNJ) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Johnson & Johnson trades at $256.47 (market cap $622.84B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.63 (market cap $8.28B). The key difference: Johnson & Johnson is far larger — about 75.2× Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)'s market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays the higher dividend (4.85%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days on average.
| JNJ | UGP | |
|---|---|---|
Market Cap | $622.84B | $8.28B |
Volume | 5,277,426 | 3,583,950 |
Sector | Health | Energy |
52-Week High | $278.43 | $7.79 |
52-Week Low | $186.00 | $3.63 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $651.12B | $10.35B |
Dividend Yield | 2.07% | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
